Novartis pays $ 100M to get Mallinckrodt’s ticket for a speedier FDA drug review
Novartis is paying $ 100 million now for the opportunity to shorten the regulatory review of a rare disease drug candidates in the indeterminate future, a move that could save time and bring a potential blockbuster product to the market sooner, assuming it passes FDA muster. The Swiss pharmaceutical giant has reached a deal to … Read more